Recent news on Adenoscan

CV Therapeutics Submits New Drug Application For Regadenoson  -  May 15, 2007
PipelineReview.com (press release),All study participants received a clinically indicated baseline MPI study using Adenoscan(R) (adenosine injection). Participants then were randomized to

King Pharmaceuticals Swings To Profit In Q4, Revenues Up 21% - Update  -  Feb 28, 2007
Trading Markets,Royalty revenues, derived primarily from Adenoscan, were $20 million for the quarter. Net revenue from contract manufacturing was $3 million in the quarter.

King Pharmaceuticals Reports Year-End and Fourth-Quarter 2006 ...  -  Feb 28, 2007
PharmaLive.com (press release),Royalty revenues, derived primarily from ADENOSCAN(R) (adenosine), totaled $20 million during the fourth quarter of 2006 and $80 million for the year ended

Astellas Terminates Agreement On Acute Heart Failure Agent Carperitide  -  Jan 28, 2007
Medical News Today (press release),...the marketing of such products as Adenoscan(R), a pharmacologic stress agent in pharmaceutical stress testing; Vaprisol(R) for euvolemic hyponatremia;

Astellas Terminates Agreement on Acute Heart Failure Agent Carperitide  -  Jan 11, 2007
PharmaLive.com (press release),...and the marketing of such products as Adenoscan®, a pharmacologic stress agent in pharmaceutical stress testing; Vaprisol® for euvolemic hyponatremia;

Regadenoson Meets Primary Endpoint in Second Phaase 3 Clinical Trial  -  Dec 5, 2006
PipelineReview.com (press release),All study participants received a clinically indicated baseline MPI study using Adenoscan(R) (adenosine injection). Participants then were randomized in a

CV Therapeutics shares rise on heart agent news  -  Dec 4, 2006
ReutersThe study compared the agent, regadenoson, with a current injectible agent called Adenoscan in patients undergoing a heart stress test called myocardial

CV Therapeutics Agent Does Well in Trail  -  Dec 4, 2006
Forbes,CV Therapeutics (nasdaq: CVTX - news - people ) said in late-stage trials regadenoson was comparable to Adenoscan, another drug used in MPI studies.

CV Therapeutics Agent Does Well in Trail  -  Dec 4, 2006
Houston Chronicle,CV Therapeutics said in late-stage trials regadenoson was comparable to Adenoscan, another drug used in MPI studies. If regadenoson is approved by the FDA,

CV Therapeutics (CVTX) Said Regadenoson Met Primary Endpoint  -  Dec 4, 2006
StreetInsider.com (subscription),...with 95 percent confidence that MPI studies conducted with regadenoson were comparable to MPI studies conducted with Adenoscan (adenosine injection).

Genzyme Introduces New Genetic Test and Gilead Stock Jumps  -  Dec 5, 2006
Financial News USA (press release),CV Therapeutics said in late-stage trials regadenoson was comparable to Adenoscan, another drug used in MPI studies. Shares of biopharmaceutical company

CV Therapeutics cardiac drug meets study goal  -  Dec 4, 2006
Pharmaceutical Business Review...its primary endpoint by showing with 95% confidence that MPI studies conducted with regadenoson were comparable to MPI studies conducted with adenoscan.

King Pharmaceuticals Reports Third-Quarter 2006 Financial Results  09 Nov 2006
Royalty revenues, derived primarily from Adenoscan ® (adenosine), totaled $19 million during the third quarter ended September 30, 2006, compared to $22 ... -Business Wire (press release), Regadenoson Meets Primary Endpoint in Second Phaase 3 Clinical Trial  -  Dec 5, 2006
PipelineReview.com (press release),All study participants received a clinically indicated baseline MPI study using Adenoscan(R) (adenosine injection). Participants then were randomized in a

CV Therapeutics shares rise on heart agent news  -  Dec 4, 2006
ReutersThe study compared the agent, regadenoson, with a current injectible agent called Adenoscan in patients undergoing a heart stress test called myocardial

CV Therapeutics Agent Does Well in Trail  -  Dec 4, 2006
Forbes,CV Therapeutics (nasdaq: CVTX - news - people ) said in late-stage trials regadenoson was comparable to Adenoscan, another drug used in MPI studies.

CV Therapeutics Agent Does Well in Trail  -  Dec 4, 2006
Houston Chronicle,CV Therapeutics said in late-stage trials regadenoson was comparable to Adenoscan, another drug used in MPI studies. If regadenoson is approved by the FDA,

CV Therapeutics (CVTX) Said Regadenoson Met Primary Endpoint  -  Dec 4, 2006
StreetInsider.com (subscription),...with 95 percent confidence that MPI studies conducted with regadenoson were comparable to MPI studies conducted with Adenoscan (adenosine injection).

Genzyme Introduces New Genetic Test and Gilead Stock Jumps  -  Dec 5, 2006
Financial News USA (press release),CV Therapeutics said in late-stage trials regadenoson was comparable to Adenoscan, another drug used in MPI studies. Shares of biopharmaceutical company

CV Therapeutics cardiac drug meets study goal  -  Dec 4, 2006
Pharmaceutical Business Review...its primary endpoint by showing with 95% confidence that MPI studies conducted with regadenoson were comparable to MPI studies conducted with adenoscan.

King Pharmaceuticals reports 8% second quarter total revenues ...  Aug 9, 2006
Royalty revenues, derived primarily from Adenoscan(R) (adenosine), totaled $21 million during the second quarter ended June 30, 2006, compared to $20 million ... -Kingsport Times News



King Pharma Q1 Adj. EPS Beats Street Expectations; Revenues Climb ...  May 9, 2006
Royalty revenues, derived primarily from Adenoscan (adenosine), totaled $20 million during the first quarter ended March 31, 2006, compared to $18 million ... - Trading Markets

King Pharmaceuticals Reports First-Quarter 2006 Financial Results  May 9, 2006
Royalty revenues, derived primarily from Adenoscan(R) (adenosine), totaled $20 million during the first quarter ended March 31, 2006, compared to $18 million ... - PR Newswire



'Tentative' FDA nod on Teva drug  Feb 13, 2006
On final approval, the injection will be the AP-rated generic equivalent of Astellas Adenoscan Injection, a product used as an supplement to thallium-201 ... - Jerusalem Post,

Teva Announces Tentative Approval of Adenosine Injection  Feb 13, 2006
Upon final approval, Teva's Adenosine Injection will be the AP-rated generic equivalent of Astellas Adenoscan(R) Injection, a product indicated as an adjunct ... - Genetic Engineering News,

Williams-Labadie Promotes Jim Grossmann to Senior Vice President ...  Jan 13, 2006
During that time, he has directed a wide range of innovative marketing programs to support the growth of Adenoscan® -- the largest brand in the Astellas ... - PharmaLive.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional